Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY

Objectif

"Despite the transformative potential of CAR-T cell therapies, their widespread adoption is hindered by significant barriers, including prohibitive costs, severe toxicities, logistical challenges in manufacturing, and limited efficacy. The iN-KEY consortium aims to overcome these challenges by developing and clinically validating a next-generation, ""off-the-shelf"" immunotherapy platform for the treatment of Multiple Myeloma (MM). At the heart of this project is a disruptive platform based on engineered induced Pluripotent Stem Cells (iPSCs). This platform integrates several key innovations: 1) Highly immunocompatible, haplo-matched iPSC lines for broad allogeneic use; 2) A proprietary, high-capacity Docking Platform (DoP) for safe, precise, and multiplexed integration of effector genes, eliminating the risks associated with viral vectors; 3) A dual-targeting strategy combining a Chimeric Antigen Receptor (CAR) against BCMA and a Synthetic T-cell Activating Bifunctional (STAb) construct against CD19; and 4) A suite of additional effector genes to enhance cell persistence, homing, and safety. This therapeutic product will be manufactured using a scalable, automated, and feeder-free GMP process, with quality control enhanced by novel multi-omics and AI-driven methodologies to ensure product consistency and safety. The project will culminate in a first-in-human clinical trial to assess the safety and preliminary efficacy of the therapy in patients with relapsed/refractory Multiple Myeloma. By addressing the core challenges of scalability, safety, accessibility, and cost, the iN-KEY platform has the potential to unlock a new generation of complex, affordable, and highly effective immunotherapies, benefiting patients and healthcare systems across Europe and beyond."

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-RIA - HORIZON Research and Innovation Actions

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-HLTH-2025-01

Voir tous les projets financés au titre de cet appel

Coordinateur

BANC DE SANG I TEIXITS
Contribution nette de l'UE
€ 2 475 046,25
Coût total
€ 2 475 046,25

Participants (12)